Effect of partial inhibition of fatty acid oxidation by trimetazidine on whole body energy metabolism in patients with chronic heart failure

Gabriele Fragasso, Anna Salerno, Guido Lattuada, Amarild Cuko, Giliola Calori, Antonella Scollo, Francesca Ragogna, Francesco Arioli, Giorgio Bassanelli, Roberto Spoladore, Livio Luzi, Alberto Margonato, Gianluca Perseghin

Research output: Contribution to journalArticlepeer-review

Abstract

Objective: Trimetazidine may have beneficial effects on left ventricular (LV) function in patients with systolic heart failure. The authors assessed whether long-term addition of trimetazidine to conventional treatment could improve, along with LV function, resting whole body energy metabolism in patients with chronic systolic heart failure. Design: Single blind randomised study. Setting: University Hospital. Patients: 44 patients with systolic heart failure receiving full medical treatment. Interventions: Indirect calorimetry and two-dimensional echocardiography at baseline and after 3 months. Main outcome measures: Whole body resting energy expenditure (REE), percentage of predicted REE, LV ejection fraction (EF), NYHA class, quality of life. Results: Trimetazidine increased EF compared with conventional therapy alone (from 3568% to 42611% vs from 3567% to 36±6%; p=0.02, analysis of variance for repeated measures). NYHA class and quality of life also improved compared with conventional therapy (p

Original languageEnglish
Pages (from-to)1495-1500
Number of pages6
JournalHeart
Volume97
Issue number18
DOIs
Publication statusPublished - Sep 2011

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Effect of partial inhibition of fatty acid oxidation by trimetazidine on whole body energy metabolism in patients with chronic heart failure'. Together they form a unique fingerprint.

Cite this